Medicare does not generally cover semaglutide when prescribed only for weight loss. Federal law has long classified drugs used primarily for obesity as excluded from Part D coverage. This restriction applies to Wegovy, the semaglutide brand approved specifically for chronic weight management.
Ozempic, the same drug approved for type 2 diabetes, usually receives coverage when prescribed for that diagnosis or related conditions like cardiovascular risk reduction. Many beneficiaries use it off-label for weight loss, but Medicare will not pay for that purpose alone.
Recent policy discussions and pilot programs have started to create limited exceptions. Understanding the exact rules helps beneficiaries plan realistically and explore alternatives when coverage is unavailable.
Federal Law That Blocks Coverage for Weight Loss
The Social Security Act contains a specific exclusion for drugs intended to treat obesity or promote weight loss. This provision dates back decades and treats anti-obesity medications differently from treatments for diabetes, heart disease, or other chronic illnesses.
Medicare Part D follows this rule strictly. Medications like Wegovy, which carry an FDA-approved indication for chronic weight management in adults with obesity or overweight plus comorbidities, fall under the exclusion. Claims for weight-loss-only use are rejected automatically.
The exclusion does not apply when the drug treats an underlying condition that qualifies for coverage. Type 2 diabetes, established atherosclerotic cardiovascular disease, or chronic kidney disease in diabetic patients opens the door to Ozempic coverage under standard Part D rules.
Off-label use for weight loss without a covered diagnosis does not change the outcome. Even if a doctor documents medical necessity, the federal statute overrides plan-level decisions.
Coverage for Ozempic When Used for Diabetes
Ozempic qualifies for Medicare Part D coverage when prescribed for type 2 diabetes management. Beneficiaries pay standard copays or coinsurance after meeting the annual deductible. Many plans place it in Tier 3 or higher, leading to costs of $50–$100 per month depending on the formulary.
Additional approved indications strengthen coverage. Ozempic reduces major cardiovascular events in patients with type 2 diabetes and established heart disease. It also lowers kidney disease progression risk in diabetic patients with albuminuria. These benefits keep it on most Part D formularies.
Medicare Advantage plans with prescription drug coverage follow the same guidelines. Some offer extra benefits like reduced copays for diabetes medications or wellness programs that indirectly support weight management.
Regular refills require ongoing documentation of diabetes diagnosis and monitoring. Labs showing A1C levels or other markers help maintain uninterrupted coverage.
Here are typical costs for covered Ozempic under Part D in 2026:
- Deductible phase: Full cost until met (up to $590 in many plans)
- Initial coverage phase: Copay $40–$100 or 25% coinsurance
- Coverage gap (donut hole): 25% coinsurance for brand-name drugs
- Catastrophic coverage: $0–$11.20 copay per fill
Wegovy Coverage Under Current Medicare Rules
Wegovy remains uncovered for its primary indication of chronic weight management. Medicare beneficiaries who qualify only for obesity treatment must pay the full list price out of pocket if they want to use it.
List price for Wegovy exceeds $1,300 per month at retail pharmacies. Manufacturer self-pay programs through NovoCare reduce this to $199 introductory then $349–$499 monthly for eligible patients without government insurance, but Medicare beneficiaries are generally excluded from these discounts.
Some physicians prescribe Ozempic off-label for weight loss in diabetic patients who also meet obesity criteria. If the primary diagnosis remains type 2 diabetes, Medicare covers the prescription. This workaround is common but depends on honest medical documentation and the doctor’s willingness.
Off-label prescribing carries no guarantee of coverage. If the claim is flagged as weight-loss focused, it can be denied even with a diabetes code.
Limited Exceptions and Pilot Programs
Medicare has introduced targeted exceptions through the Center for Medicare and Medicaid Innovation. Starting in 2026, certain pilot models allow coverage of GLP-1 drugs like Wegovy for select beneficiaries with severe obesity and high-risk conditions.
These programs focus on patients with BMI over 35 plus serious comorbidities such as heart failure, coronary artery disease, or uncontrolled type 2 diabetes. Enrollment is limited and often requires participation in monitored lifestyle interventions.
The pilots aim to test whether covering anti-obesity medications reduces long-term healthcare spending on complications like heart attacks or joint replacements. Positive results could lead to broader policy changes in future years.
Participation is not automatic. Beneficiaries must meet strict eligibility and often live in designated regions or be assigned to participating plans.
Medicare Advantage Plans and Extra Benefits
Medicare Advantage plans must follow Part D rules for prescription coverage. Weight-loss-only exclusions apply equally to Advantage plans with drug benefits.
Some Advantage plans offer supplemental benefits that indirectly help with weight management. These may include gym memberships, nutrition counseling, or over-the-counter allowances for healthy food items. None currently cover Wegovy for obesity alone.
A few plans experiment with enhanced coverage for GLP-1s in high-risk groups under special supplemental benefits. These vary by carrier and region, so checking the Evidence of Coverage document is essential.
Dual-eligible beneficiaries with Medicare and Medicaid may access coverage through state Medicaid programs. Some states cover Wegovy for obesity, but rules differ widely.
Comparison of Semaglutide Coverage Under Medicare
| Medication & Indication | Medicare Part D Coverage | Typical Out-of-Pocket Cost |
|---|---|---|
| Ozempic (Type 2 Diabetes) | Usually covered | $40–$100 copay |
| Ozempic (Off-Label Weight Loss) | Not covered if primary use | Full price (~$1,000+) |
| Wegovy (Chronic Weight Management) | Not covered | Full price or self-pay discount |
| Wegovy (Other Qualifying Use) | Covered if meets criteria | Standard Part D cost |
Coverage hinges on the documented primary indication. Diabetes unlocks access, while obesity-only use blocks it under current law.
Out-of-Pocket Options When Medicare Denies Coverage
Manufacturer self-pay programs through NovoCare provide Wegovy at $199 introductory then $349 monthly for eligible patients. Medicare beneficiaries are often excluded, but some navigate around this with careful eligibility checks.
Compounded semaglutide from licensed telehealth providers costs $199–$399 monthly. These versions include virtual consultations and home delivery but are not FDA-approved and carry more variability in quality.
Patient assistance foundations help low-income Medicare beneficiaries in limited cases. Applications require financial proof and physician support, and approval is not guaranteed.
Paying full retail price at a pharmacy remains an option but costs $1,000+ per month and faces frequent shortages.
Steps to Check and Improve Coverage Chances
Review your plan’s formulary and Evidence of Coverage document. Search for Ozempic or semaglutide to see tier placement and any weight-related exclusions.
Contact Medicare or your Part D plan directly with questions. Ask about any pilot programs or supplemental benefits that might apply to your situation.
Work with your doctor to document all qualifying conditions. If you have type 2 diabetes, prediabetes, or cardiovascular disease, make sure these appear prominently in records.
Appeal any denial promptly. Submit additional labs, specialist notes, or comorbidity evidence. Peer-to-peer reviews sometimes overturn initial rejections.
Explore non-covered options like compounded semaglutide if appeals fail. Choose providers with strong safety records and physician oversight.
Alternatives When Coverage Remains Unavailable
Other GLP-1 drugs like liraglutide (Saxenda) face similar exclusions but may have different self-pay pricing. Discuss switching if semaglutide access stays blocked.
Intensive behavioral therapy for obesity is covered under Medicare in certain settings. Sessions with dietitians or psychologists can support weight loss without medication.
Bariatric surgery qualifies for coverage in eligible patients with BMI over 35 plus comorbidities. It offers more permanent results but involves higher upfront risk.
Lifestyle programs through Medicare Advantage extras, such as SilverSneakers or nutrition coaching, provide free or low-cost support. These build habits that enhance any future treatment.
Long-Term Implications of Coverage Limits
Lack of coverage forces many seniors to pay high out-of-pocket costs or go without effective treatment. This contributes to ongoing health disparities in older adults with obesity-related conditions.
Untreated obesity increases risks for heart disease, stroke, joint problems, and diabetes complications. Medicare spending on these conditions often exceeds the cost of preventive medications.
Advocacy groups continue pushing for repeal of the obesity exclusion. Congressional bills have proposed changes, but progress remains slow.
Beneficiaries should stay informed about policy updates. Annual plan changes or new pilots may open coverage doors in future enrollment periods.
Conclusion
Medicare does not cover semaglutide for weight loss alone due to a long-standing federal exclusion, though Ozempic receives coverage when used for type 2 diabetes or certain related conditions. Limited pilot programs offer hope for exceptions in high-risk cases, but most beneficiaries must pay out of pocket or seek compounded alternatives. Work with your doctor and plan to explore every possible pathway for access.
FAQ
Does Medicare Part D pay for Wegovy for weight loss?
No, federal law excludes drugs used primarily for obesity or weight loss from Part D coverage. Wegovy falls under this rule and is not covered when prescribed only for weight management.
Can I get Ozempic covered by Medicare if I also have obesity?
Yes, if the primary diagnosis is type 2 diabetes or another covered indication like cardiovascular risk reduction. Weight loss must not be listed as the main reason for the prescription.
Are there any 2026 Medicare programs that cover semaglutide for obesity?
Certain Innovation Center pilot models allow limited coverage for high-risk beneficiaries with severe obesity and comorbidities. These are not widespread and require specific eligibility.
What if my doctor prescribes Ozempic off-label for weight loss?
Medicare will likely deny the claim if weight loss is the documented primary purpose. Off-label use works only when a covered condition like diabetes is the main indication.
What are my options if Medicare denies semaglutide coverage?
Pay out of pocket through manufacturer self-pay programs ($349–$499 monthly), use compounded versions from telehealth providers ($199–$399), or apply for patient assistance if income qualifies. Discuss alternatives with your doctor.
Dr. Usman is a medical content reviewer with 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic health topics. His work is based on trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Usman is for educational purposes and does not replace professional medical advice.